First-line serplulimab-based immunochemotherapy in elderly patients with extensive-stage small cell lung cancer: a multicenter, real-world study
This study showed that combining serplulimab with chemotherapy improved survival and reduced toxicity in elderly ES-SCLC patients. Additionally, NLR may not be suitable as a biomarker for the elderly ES-SCLC population.
Authors
- Wenyue Yang (ORCID: https://orcid.org/0000-0001-9357-4334)
- Yun Zhou (ORCID: https://orcid.org/0000-0002-3757-6674)
- Min Zhou (ORCID: https://orcid.org/0000-0002-6831-3033)
- Xiaodong Xia (ORCID: https://orcid.org/0000-0002-6336-2661)
- Jialei Wang (ORCID: https://orcid.org/0000-0001-6944-9613)
- Meiqi Shi (ORCID: https://orcid.org/0000-0002-3578-4082)
- Xinli Zhou (ORCID: https://orcid.org/0000-0001-8517-4496)
Institutions
- China Pharmaceutical University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Jiangsu Cancer Hospital (CN)
Publication Details
- Journal
- Journal of Thoracic Disease
- Published
- 2025-05-01
- DOI
- https://doi.org/10.21037/jtd-24-1815
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00